Dra. María Natalia Gandur Quiroga’s Post

🌟 Breakthrough in Prostate Cancer Treatment! 🌟 Oral cyclophosphamide has emerged as a promising treatment for metastatic castration-resistant prostate cancer (mCRPC) in resource-limited settings, as highlighted by a recent study conducted in São Paulo, Brazil. 📊 Study Insights: - Over 341 mCRPC patients treated between 2011-2023. - A daily regimen of 100 mg for 21 days showed significant results: - 33.4% experienced a decline in PSA levels. - 13.2% achieved a PSA50 response. 🔍 Key Takeaways: - Effective even after multiple treatment lines. - Higher success rates observed in patients without prior docetaxel treatment and those with better performance status. This study underscores the importance of accessible treatments for mCRPC, especially where advanced therapies are scarce. 💡 Future research should focus on combination therapies and identifying biomarkers to optimize patient outcomes. 👉 Click the link to learn more about this vital advancement! #CancerResearch #ClinicalResearches #HealthcareInnovation #Oncology #PatientCare #ProstateCancer #Publications #RegulatoryAgencies #MarketAccess #MarketAccessToday

Novartis Kisqali gets European Commission nod in patients with HR+/HER2-early breast cancer at high risk of recurrence  Novartis has announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence. The approval is based on results from the pivotal Phase III NATALEE trial, which included a broad patient population with HR+/HER2- stage II and III EBC, including those with node-negative disease. The trial showed a significant and clinically meaningful 25.1% (HR=0.749; 95% CI: 0.628, 0.892; P=0.0006) reduction in risk of disease recurrence with adjuvant Kisqali plus endocrine therapy (ET) compared to ET alone. The invasive disease-free survival (iDFS) benefit was consistently observed across all patient subgroups. #novartis #novartisnews #kisqali #ribociclib #breastcancer

Discover how the Asia-Pacific Hepatocellular Carcinoma (AHCC) Trials Group, led by Protocol Chair Professor Pierce Chow, is tackling the HCC epidemic in the region. With over 25 years of pioneering research, 62 participating centres, and 4,000+ patients enrolled in groundbreaking studies, AHCC is making strides in early diagnosis, innovative treatments, and collaborative efforts to improve patient outcomes. Learn more about their key achievements, ongoing trials, and commitment to advancing HCC care in our latest article. Together, we're driving progress against liver cancer and fostering a spirit of regional cooperation. Read the full article here: https://lnkd.in/gZBJTPA9

Over the last decade, cancer research in Asia has evolved significantly, moving beyond individual hospitals to form consortia that unite leading experts and institutions in an otherwise hyper-fragmented APAC landscape. At Oncoshot, we are excited to support these consortia, exploring new ways to accelerate research and clinical trial opportunities across the region while respecting the needs of both participating institutes and the consortia. Our latest blog post highlights the #Asia-Pacific Hepatocellular Carcinoma (#AHCC) Trials Group, a consortium focused on liver cancer—a critical area of need in Asia, which bears the largest burden of liver cancer globally. The AHCC is making significant strides in research and drug development by bringing together 62 centers across 17 countries, fostering collaboration and innovation in the fight against hepatocellular carcinoma. Learn more about how this consortium is advancing liver cancer care through research and therapeutic trials.

ConcertAI is privileged and proud to advance this research at the American Society of Clinical Oncology (ASCO) GI Cancers Symposium meeting this coming Saturday, January 25, with our colleagues at Taiho Oncology, Inc.. These findings underscore the importance of combination therapy (FTD-TPI+bevacizumab) in improving outcomes for Black patients with mCRC, a population historically underrepresented in clinical research. This study emphasizes the need for more inclusive data to ensure equitable treatment advances for all. #taiho #concertai #healthequity

Join us on Saturday, January 25th from 7:00-7:55 AM at the 2025 ASCO Gastrointestinal Cancers Symposium for a poster session titled “Real-world clinical outcomes of trifluridine-tipiracil monotherapy (FTD-TPI) and FTD-TPI + bevacizumab combination therapy (FTD-TPI+bev) in 639 black patients (pts) with metastatic colorectal cancer (mCRC).” New findings from a large real-world analysis highlight the clinical outcomes of trifluridine-tipiracil (FTD-TPI) monotherapy and FTD-TPI combined with bevacizumab (FTD-TPI+bev) in 639 Black patients with metastatic colorectal cancer (mCRC). Using US-based electronic medical records and claims in the ConcertAI RWD360 dataset results showed that FTD-TPI+bev significantly improved overall survival (10.8 vs. 6.2 months) and time to treatment discontinuation (3.8 vs. 2.4 months) compared to FTD-TPI monotherapy. Adjusted analyses confirmed these findings, with FTD-TPI+bev associated with a 55% lower risk of death and a 49% lower risk of discontinuation. These findings are consistent with the overall SUNLIGHT trial results and underscore the importance of combination therapy in improving outcomes for Black patients with mCRC, a population historically underrepresented in clinical research. This study emphasizes the need for more inclusive data to ensure equitable treatment advances for all. Read abstract: https://hubs.ly/Q033CS5V0

🚀 Duration of Targeted Therapy in Advanced Cancer Treatment 🚀 🔬 Exciting advancements in cancer research have shown that targeted therapy regimens, such as the use of tyrosine kinase inhibitors (TKIs), play a crucial role in managing advanced cancers. Our latest publication in The Lancet Oncology explores the long-term outcomes of imatinib treatment in patients with advanced gastrointestinal stromal tumors (GIST). 📊 Key Findings from the BFR14 Study: Imatinib Continuation vs. Interruption: The study compared the effects of continuing imatinib treatment versus interrupting it after 1, 3, and 5 years in patients with advanced GIST. Impact on Progression-Free Survival: Patients who continued imatinib had significantly longer progression-free survival compared to those who interrupted treatment. Resistance and Survival: Continuous treatment delayed the development of resistance and improved overall survival, particularly noticeable in the cohorts followed for 3 and 5 years. 👩⚕️👨⚕️ Clinical Implications: Avoiding Treatment Interruption: Interrupting TKI treatment in non-progressing patients can lead to rapid disease progression and faster development of drug resistance. Patient Outcomes: Ensuring continuous therapy in patients with advanced disease can significantly enhance their overall survival and quality of life. 🌟 Highlight: Our findings underscore the importance of maintaining consistent targeted therapy in managing advanced GIST. While treatment discontinuation may be safe in other indications, it should be properly evaluated in randomized clinical studies before being proposed to patients. In the context of GIST, treatment discontinuation has been shown to be unsafe. 💡 This research not only advances our understanding of GIST management but also has broader implications for other cancers treated with TKIs. Careful evaluation through randomized clinical trials is essential before considering targeted therapy discontinuation. 🔗 Read the full study here: : https://lnkd.in/esbWZ7bF #CancerResearch #TargetedTherapy #GIST #Oncology #ClinicalTrials #MedicalResearch #Imatinib #PatientCare

Fundamental results on the interruption-continuation aspect of targeted therapy with TKi

APAC is the hot bed for HCC…with 80% of the worlds diagnosis and a need to improve mortality rates. Early diagnosis always helps…but is very difficult to do effectively and stay affordable. Tackling this problem is the AHCC - a clinical trial group consisting of 62 pioneering clinical Centres. Their work is showcased here. #oncology #clinicaltrials #oncoshot #oncopericia #cancercare #cancerresearch

The TAR-210 study unveils groundbreaking findings in #bladdercancer treatment, presenting a promising new approach for high-risk and intermediate-risk patients. Johnson & Johnson's intravesical targeted releasing system, delivering #erdafitinib (#Balversa®) locally, demonstrated impressive efficacy with a 90% recurrence-free survival rate and complete response rates. Commenting on the significance of these results, Dr. Prof. Dr. med. Sabine D. Brookman-May, Vice President of Late Development Oncology at Johnson & Johnson Innovative Medicine, highlighted the potential of TAR-210 as a bladder-sparing and BCG-free treatment option. "FGFR genetic alterations are most common in NMIBC," she noted, "These results further support the potential of TAR-210 with quarterly administration as a bladder-sparing and BCG-free treatment option, underscoring our deep commitment to pioneering novel therapies for patients who face limited treatment avenues." #bladder #cancer https://lnkd.in/d2uivCWN